Event-Driven Stocks

Xencor Inc

XNCRNasdaq

Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 3 good● 4 warningdetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue$125.6M$110.5M$174.6M$164.6M$275.1M$122.7M
Operating income−$177.5M−$178.4M−$132.4M−$82.5M$43.8M−$76.8M
Net income−$91.9M−$232.6M−$133.1M−$55.2M$82.6M−$69.3M
Total assets$875.5M$951.9M$965.1M$846.3M$838.2M$703.2M
Total liabilities$239.9M$277.9M$303.0M$118.8M$104.7M$130.8M
Equity$635.6M$677.6M$661.8M$727.5M$733.5M$572.4M
EPS (diluted)$-1.24$-3.58$-2.20$-0.93$1.37$-1.21
Shares out.70.5M61.1M60.0M59.4M57.9M56.9M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
−141.4%
Net margin
−73.2%
Return on equity
−14.5%
Return on assets
−10.5%
Return on capital (ROCE)
−22.8%
Liabilities / assets
27.4%
Debt / equity
0.38×
Book value / share
$9.02
Revenue growth (YoY)
13.7%
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Altman Z″ (distress)
2.23grey zone
Accruals / assets
4.9%clean
Piotroski F-Score
4/9mixed

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
48
/ 100
Profitability 0Growth 100Catalyst 33Earnings quality 33Financial strength 75

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →

Signs

● 4 warning● 3 good
  • Operating losses (negative operating margin)
  • Reported a net loss
  • Negative operating cash flow
  • Altman Z″ in the grey zone
  • Revenue is growing year-over-year
  • Conservative leverage (liabilities < 50% of assets)
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 202610.7M12.9+1.7%
Apr 30, 202610.5M15.6+2.1%
Apr 15, 202610.3M13.0-8.7%
Mar 31, 202611.3M11.3+0.7%
Mar 13, 202611.2M12.6-0.2%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (1)

Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.